Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

10. Oktober 2017 07:00 ET | Quelle: Shield Therapeutics

Shield Therapeutics plc ("Shield" or the "Group") Completion of patient enrolment in pivotal AEGIS-CKD Phase 3 study

LONDON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces the completion of enrollment of the pivotal...
06. September 2017 07:00 ET | Quelle: Shield Therapeutics

Shield Therapeutics plc ("Shield" or the "Group") US Composition of Matter Patent

LONDON, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, is pleased to announce that the United States Patent and...
31. August 2017 09:00 ET | Quelle: Shield Therapeutics

Shield Therapeutics plc to Present at the Baird Global Healthcare Conference on Wednesday, September 6, 2017

LONDON, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announced that Carl Sterritt, Chief Executive...
20. September 2016 08:42 ET | Quelle: Shield Therapeutics

Interim Results for the six months ended 30 June 2016

LONDON, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, today announces its preliminary Group results for...